Investment Rating - The report maintains an "Overweight" rating for the computer industry [1] Core Insights - The brain-computer interface (BCI) technology is a key focus in the "14th Five-Year Plan," with continuous technological breakthroughs expected [1][4] - The market for brain-computer interfaces in China is projected to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, indicating a broad market potential [11][12] - The report highlights significant policy support and the establishment of standards for BCI technology, which will facilitate its integration into the healthcare system [9][10][12] Summary by Sections 1. Policy and Industry Development - Frequent policies are promoting the standardization and development of the BCI industry, with the National Development and Reform Commission listing BCI as one of the ten iconic products for future industries [9] - The National Medical Insurance Administration's announcement in September 2025 aims to expedite the approval process for innovative medical consumables, including BCIs, facilitating their entry into hospitals [10] 2. Technological Breakthroughs - Clinical trials for invasive BCIs have been conducted in major hospitals, with over 30 experiments related to spinal cord injuries and ALS patients [13] - Non-invasive BCI products are gaining regulatory approval, with companies like Shaonao Technology and Aipeng Medical making significant strides in commercialization [16][19] 3. Investment Recommendations - The report suggests focusing on companies actively involved in the BCI sector, including Innovation Medical, Chengyitong, Sanbo Brain Science, and others, due to the accelerating clinical and commercial progress [21]

Core Viewpoint - Sanbo Brain Science (301293.SZ) reported a revenue of 1.273 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 20.26%. However, the net profit attributable to shareholders decreased by 20.01% to 83.6282 million yuan [1]. Financial Performance - The company's revenue for the first three quarters reached 1.273 billion yuan, marking a year-on-year increase of 20.26% [1]. - The net profit attributable to shareholders was 83.6282 million yuan, which represents a decline of 20.01% compared to the previous year [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 84.9638 million yuan, showing a decrease of 4.85% year-on-year [1]. - The basic earnings per share stood at 0.41 yuan [1].

Group 1 - Northern Rare Earth reported a net profit increase of 280% year-on-year for the first three quarters, driven by higher sales volume and prices of rare earth products [1] - Postal Savings Bank has received approval to establish a financial asset investment company with a registered capital of 10 billion yuan, aimed at enhancing comprehensive service capabilities and supporting technological innovation [2] - Silyus announced a maximum price of HKD 131.5 per share for its H-share issuance, with a total of 100.2 million shares available for global offering [3] Group 2 - Hengtong Optic-Electric won a bid for marine energy projects with a total contract value of 1.868 billion yuan, including the supply and construction of undersea cables [4] - Western Mining's subsidiary Yulong Copper won exploration rights for the Chating copper polymetallic mine for 8.609 billion yuan, which is expected to enhance the company's resource reserves [5] - China Bank appointed Liu Chenggang as vice president, effective from October 24, 2025 [6] Group 3 - ST Guangwu announced the removal of other risk warnings for its stock, changing its name to Guanghui Logistics, which will allow for a wider trading limit [7] - Wireless Media set an initial transfer price of 29.11 yuan per share for its inquiry transfer, with a subscription multiple of 2.01 times [8][9] - Jiangshan Oupai's subsidiaries in Henan and Chongqing will cease operations due to insufficient orders, with business transferred to its Zhejiang base [10] Group 4 - Zhenyu Technology plans to invest 2.11 billion yuan in precision component manufacturing and humanoid robot projects, with the first phase of investment to be signed soon [11] - Jinyuan Co. announced the resignation of its general manager, with Qiu Yongping appointed as the new general manager [12] Group 5 - CanSino reported a net profit of 27.93 million yuan for Q3, a year-on-year increase of 842.01% [13] - Jiangshan Co. reported a net profit of 86.73 million yuan for Q3, a year-on-year increase of 11,890.01% [14] - Yingshi Innovation reported a net profit of 272 million yuan for Q3, a year-on-year decrease of 15.90% [15] Group 6 - Chip Origin reported a net loss of 26.85 million yuan for Q3, despite a revenue increase of 78.38% [16] - Tonghua Dongbao reported a net profit of 984 million yuan for Q3, a year-on-year increase of 499.86% [17] - Hengrui Medicine reported a net profit of 1.301 billion yuan for Q3, a year-on-year increase of 9.53% [18] Group 7 - Zhongguang Lightning reported a net profit of 6.46 million yuan for Q3, a year-on-year increase of 382.66% [19] - Ice River Network reported a net profit of 166 million yuan for Q3, a year-on-year increase of 244.58% [20] - Daheng Technology reported a net profit of 71.48 million yuan for Q3, a year-on-year increase of 1,960.72% [21] Group 8 - Yanjin Puzhi reported a net profit of 232 million yuan for Q3, a year-on-year increase of 33.55% [22] - Sichuan Gold reported a net profit of 160 million yuan for Q3, a year-on-year increase of 184.38% [23] - Sanbo Brain Science reported a net profit of 13.93 million yuan for Q3, a year-on-year decrease of 63.26% [24] Group 9 - Hengli Petrochemical reported a net profit of 1.972 billion yuan for Q3, a year-on-year increase of 81.47% [25] - Deepin Technology reported a net profit of 147 million yuan for Q3, a year-on-year increase of 1,097.40% [26] - Huisheng Biological reported a net profit of 70.72 million yuan for Q3, a year-on-year increase of 1,575.79% [27] Group 10 - Gaode Infrared reported a net profit of 401 million yuan for Q3, a year-on-year increase of 1,143.72% [28] - Qingdao Beer reported a net profit of 1.37 billion yuan for Q3, a year-on-year increase of 1.62% [29] - Nanjing Public Utilities reported a net profit of 84.62 million yuan for Q3, a year-on-year increase of 2,492.12% [30] Group 11 - Zhangyuan Tungsten reported a net profit of 75.02 million yuan for Q3, a year-on-year increase of 118.56% [31] - Yongmaotai reported a net profit of 30.41 million yuan for Q3, a year-on-year increase of 6,319.92% [32] Group 12 - Tongrun Equipment announced that two shareholders plan to reduce their holdings by 1.50% each, totaling a maximum of 3.00% [33] - High-speed Rail Electric announced a pre-bid for a city rail transit project worth 62.39 million yuan [34]

Group 1 - The core point of the article is that Sanbo Brain Science (SZ 301293) held its 15th meeting of the third board of directors on October 27, 2025, where it reviewed the proposal to amend the "General Manager's Work Guidelines" [1] - For the fiscal year 2024, Sanbo Brain Science's revenue composition is 99.67% from medical services and 0.33% from supply chain [2] - As of the report date, Sanbo Brain Science has a market capitalization of 12.7 billion yuan [2]

Group 1 - Company Sanbo Brain Science reported a revenue of approximately 1.273 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 20.26% [1] - The net profit attributable to shareholders of the listed company was approximately 83.63 million yuan, showing a year-on-year decrease of 20.01% [1] - The basic earnings per share were 0.41 yuan, which is a year-on-year decrease of 19.61% [1] Group 2 - As of the report date, the market capitalization of Sanbo Brain Science is 12.7 billion yuan [2]

Core Insights - The company reported Q3 2025 revenue of 446 million yuan, representing a year-on-year increase of 25.65% [1] - Net profit for Q3 2025 was 13.93 million yuan, showing a significant decline of 63.26% year-on-year [1] - For the first three quarters of 2025, total revenue reached 1.273 billion yuan, up 20.26% compared to the previous year [1] - Net profit for the first three quarters was 83.63 million yuan, down 20.01% year-on-year [1]

三博脑科医院管理集团股份有限公司 章 程 2025 年 10 月 1 | | | 三博脑科医院管理集团股份有限公司 章程 第一章 总则 第一条 为维护三博脑科医院管理集团股份有限公司（以下简称"公司"）、 股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定由三博医院管理集团有限公 司整体变更设立的股份有限公司。公司在北京市海淀区市场监督管理局注册登记， 现持有统一信用代码为 91110108756735293H 的《营业执照》。 第三条 公司于 2023 年 3 月 10 日经中国证券监督管理委员会（以下简称"中 国证监会"）同意注册，首次向社会公众发行人民币普通股 39,612,900 股，于 2023 年 5 月 5 日在深圳证券交易所创业板上市。 第四条 公司注册名称：三博脑科医院管理集团股份有限公司 公司英文全称：Sanbo Hospital Management Group Limited 第五条 公司住所：北京市海淀 ...

三博脑科医院管理集团股份有限公司 关于为子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 证券代码：301293 证券简称：三博脑科 公告编号：2025-043 根据三博脑科医院管理集团股份有限公司（以下简称"公司"）发展战略和业 务布局的规划，为满足未来发展中的资金需求，公司子公司昆明三博脑科医院有 限公司、昆明浩源医疗管理有限公司、西安三博脑科医院有限公司、成都三博东 篱医院有限公司、北京三博脑科医院有限公司、三博（重庆）物业管理有限公司 （以下分别简称"昆明三博"、"昆明浩源"、"西安三博"、"成都三博"、"北京三博"、 "三博重庆物业"）拟向银行（包括但不限于招商银行、浙商银行、建设银行、上 海银行、工商银行、中信银行、民生银行、兴业银行、西安银行、秦农银行等金 融机构申请综合授信、项目贷款、流动资金贷款等融资业务，其中昆明三博及昆 明浩源拟共同融资不超过 18,497.94 万元、西安三博拟融资不超过 9,135.95 万元、 成都三博拟融资不超过 3,000 万元、北京三博拟融资不超过 36,608.9 ...

为不断提高公司管理效率，保证公司合规运作，现对《公司章程》部分条款 予以修订，具体如下： | | 修订前 | 修订后 | | --- | --- | --- | | 第一百一十八条 | 董事长行使下列职 | 第一百一十八条 董事长行使下列职 | | 权： | | 权： | | （一）主持股东会和召集、主持董 | | （一）主持股东会和召集、主持董 | | 事会会议； | | 事会会议； | | （二）督促、检查董事会决议的执 | | （二）督促、检查董事会决议的执 | | 行； | | 行； | | （三）依法行使法定代表人的职 | | （三）依法行使法定代表人的职 | | 权； | | 权； | | （四）董事会授予的其他职权。 | | （四）董事会秘书由董事长提名， | | | | 同时董事长可以决定公司副总经理、财 | | | | 务总监提名人选； | | | | （五）对于无需公司董事会决定聘 | | | | 任或者解聘以外的负责管理人员，总监 | | | | 级别以上的管理层由董事长决定聘任 | | | | 或者解聘。 | | | | （六）三博脑科按出资比例向子公 | | | | 司委派或推荐董事 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-045 三博脑科医院管理集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 11 月 06 日 7、出席对象： （1）于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体已发行有表 决权股份的股东均有权出席股东会，并可以以书面形式委托代理人出席会议和参加表决， 该股东代理人不必是本公司股东； 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 12 日 15:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票 ...